{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:25:42Z","timestamp":1740176742643,"version":"3.37.3"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"DOI":"10.1007\/s00261-023-03967-1","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T14:06:06Z","timestamp":1686319566000},"page":"3012-3021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Computed tomography findings of hepatobiliary systems in patients with immune checkpoint inhibitor-induced liver injury"],"prefix":"10.1007","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4163-6542","authenticated-orcid":false,"given":"Sota","family":"Masuoka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3274-4341","authenticated-orcid":false,"given":"Takashi","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4337-2782","authenticated-orcid":false,"given":"Hirofumi","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6811-2381","authenticated-orcid":false,"given":"Tomoaki","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6818-2574","authenticated-orcid":false,"given":"Shioto","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2493-0718","authenticated-orcid":false,"given":"Yusuke","family":"Miyasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9474-1154","authenticated-orcid":false,"given":"Masayuki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7310-2097","authenticated-orcid":false,"given":"Tatsushi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"3967_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","volume":"6","author":"M Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M, Brahmer JR, Callahan MK et al (2020) Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 6:38. https:\/\/doi.org\/10.1038\/s41572-020-0160-6","journal-title":"Nat Rev Dis Primers"},{"key":"3967_CR2","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Shao C, Shi Y, Han W (2018) Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol 11:31. https:\/\/doi.org\/10.1186\/s13045-018-0578-4","journal-title":"J Hematol Oncol"},{"key":"3967_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD (2018) Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 378:158-168. https:\/\/doi.org\/10.1056\/NEJMra1703481","journal-title":"N Engl J Med"},{"key":"3967_CR4","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00261-021-02986-0","volume":"46","author":"M Kurokawa","year":"2021","unstructured":"Kurokawa M, Kurokawa R, Hagiwara A et al (2021) CT imaging findings of anti-PD-1 inhibitor-related enterocolitis. Abdom Radiol (NY) 46:3033-3043. https:\/\/doi.org\/10.1007\/s00261-021-02986-0","journal-title":"Abdom Radiol (NY)"},{"key":"3967_CR5","doi-asserted-by":"publisher","unstructured":"Kurokawa R, Ota Y, Gonoi W et al (2020) MRI findings of immune checkpoint inhibitor\u2013induced hypophysitis: possible association with fibrosis. AJNR Am J Neuroradiol A6692v1 41:1683-1689. https:\/\/doi.org\/10.3174\/ajnr.A6692","DOI":"10.3174\/ajnr.A6692"},{"key":"3967_CR6","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ et al (2018) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 36:1714-1768. https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"},{"key":"3967_CR7","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12072-018-9921-7","volume":"13","author":"N Nishida","year":"2019","unstructured":"Nishida N, Kudo M (2019) Liver damage related to immune checkpoint inhibitors. Hepatol Int 13:248-252. https:\/\/doi.org\/10.1007\/s12072-018-9921-7","journal-title":"Hepatol Int"},{"key":"3967_CR8","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1111\/his.14000","volume":"76","author":"Y Zen","year":"2020","unstructured":"Zen Y, Chen YY, Jeng YM, Tsai HW, Yeh MM (2020) Immune\u2010related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes. Histopathology 76:470-480. https:\/\/doi.org\/10.1111\/his.14000","journal-title":"Histopathology"},{"key":"3967_CR9","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1016\/j.jtho.2017.10.007","volume":"13","author":"JH Cho","year":"2018","unstructured":"Cho JH, Sun JM, Lee SH, Ahn JS, Park K, Ahn MJ (2018) Late-onset cholecystitis with cholangitis after avelumab treatment in non-small cell lung cancer. J Thorac Oncol 13:e34-e36. https:\/\/doi.org\/10.1016\/j.jtho.2017.10.007","journal-title":"J Thorac Oncol"},{"key":"3967_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10637-017-0453-0","volume":"35","author":"H Kawakami","year":"2017","unstructured":"Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529-536. https:\/\/doi.org\/10.1007\/s10637-017-0453-0","journal-title":"Invest New Drugs"},{"key":"3967_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejca.2018.11.021","volume":"107","author":"S Noda-Narita","year":"2019","unstructured":"Noda-Narita S, Mizuno S, Noguchi S et al (2019) Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab. Eur J Cancer 107:93-96. https:\/\/doi.org\/10.1016\/j.ejca.2018.11.021","journal-title":"Eur J Cancer"},{"key":"3967_CR12","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1007\/s10637-021-01136-z","volume":"39","author":"M Takinami","year":"2021","unstructured":"Takinami M, Ono A, Kawabata T et al (2021) Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis. Invest New Drugs 39:1716-1723. https:\/\/doi.org\/https:\/\/doi.org\/10.1007\/s10637-021-01136-z","journal-title":"Invest New Drugs"},{"key":"3967_CR13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) (2017), version 5.0. Washington, DC: US Department of Health and Human Services. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"key":"3967_CR14","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1148\/radiol.2018181349","volume":"290","author":"M Nishino","year":"2019","unstructured":"Nishino M, Hatabu H, Hodi FS (2019) Imaging of cancer immunotherapy: current approaches and future directions. Radiology 290:9-22. https:\/\/doi.org\/10.1148\/radiol.2018181349","journal-title":"Radiology"},{"key":"3967_CR15","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1158\/2326-6066.CIR-15-0102","volume":"3","author":"SH Tirumani","year":"2015","unstructured":"Tirumani SH, Ramaiya NH, Keraliya A et al (2015) Radiographic profiling of immune-related adverse events in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 3:1185-1192. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0102","journal-title":"Cancer Immunol Res"},{"key":"3967_CR16","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.crad.2017.04.003","volume":"72","author":"F Alessandrino","year":"2017","unstructured":"Alessandrino F, Tirumani SH, Krajewski KM et al (2017) Imaging of hepatic toxicity of systemic therapy in a tertiary cancer centre: chemotherapy, haematopoietic stem cell transplantation, molecular targeted therapies, and immune checkpoint inhibitors. Clin Radiol 72:521-533. https:\/\/doi.org\/10.1016\/j.crad.2017.04.003","journal-title":"Clin Radiol"},{"key":"3967_CR17","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","volume":"55","author":"K Mizuno","year":"2020","unstructured":"Mizuno K, Ito T, Ishigami M et al (2020) Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies. J Gastroenterol 55:653-661. https:\/\/doi.org\/10.1007\/s00535-020-01677-9","journal-title":"J Gastroenterol"},{"key":"3967_CR18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1093\/annonc\/mdw649","volume":"28","author":"F Gelsomino","year":"2017","unstructured":"Gelsomino F, Vitale G, D\u2019Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671-672. https:\/\/doi.org\/10.1093\/annonc\/mdw649","journal-title":"Ann Oncol"},{"key":"3967_CR19","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1016\/j.jhep.2007.11.019","volume":"48","author":"K Said","year":"2008","unstructured":"Said K, Glaumann H, Bergquist A (2008) Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 48:598-605. https:\/\/doi.org\/10.1016\/j.jhep.2007.11.019","journal-title":"J Hepatol"},{"key":"3967_CR20","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1148\/rg.2019180213","volume":"39","author":"P Khoshpouri","year":"2019","unstructured":"Khoshpouri P, Habibabadi RR, Hazhirkarzar B et al (2019) Imaging features of primary sclerosing cholangitis: from diagnosis to liver transplant follow-up. RadioGraphics 39:1938-1964. https:\/\/doi.org\/10.1148\/rg.2019180213","journal-title":"RadioGraphics"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-023-03967-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-023-03967-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-023-03967-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T02:03:48Z","timestamp":1692756228000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-023-03967-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":20,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["3967"],"URL":"https:\/\/doi.org\/10.1007\/s00261-023-03967-1","relation":{},"ISSN":["2366-0058"],"issn-type":[{"type":"electronic","value":"2366-0058"}],"subject":[],"published":{"date-parts":[[2023,6,9]]},"assertion":[{"value":"2 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}